Aquinox Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AQXP)

$10.56 -0.01 (-0.09 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$10.57
Today's Range$10.27 - $10.61
52-Week Range$10.20 - $19.97
Volume47,795 shs
Average Volume86,773 shs
Market Capitalization$247.79 million
P/E RatioN/A
Dividend YieldN/A
Beta-17.04

About Aquinox Pharmaceuticals (NASDAQ:AQXP)

Aquinox Pharmaceuticals logoAquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:AQXP
  • CUSIP: N/A
  • Web: aqxpharma.com
Debt:
  • Current Ratio: 17.25%
  • Quick Ratio: 17.25%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $6.18 per share
  • Price / Book: 1.71
Profitability:
  • Trailing EPS: ($1.93)
  • Net Income: $-37,000,000.00
  • Return on Equity: -34.72%
  • Return on Assets: -32.69%
Misc:
  • Employees: 38
  • Outstanding Shares: 23,470,000
 

Frequently Asked Questions for Aquinox Pharmaceuticals (NASDAQ:AQXP)

What is Aquinox Pharmaceuticals' stock symbol?

Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) released its earnings results on Tuesday, May, 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.51) by $0.15. During the same quarter last year, the business earned ($0.39) EPS. View Aquinox Pharmaceuticals' Earnings History.

Where is Aquinox Pharmaceuticals' stock going? Where will Aquinox Pharmaceuticals' stock price be in 2017?

3 brokers have issued twelve-month target prices for Aquinox Pharmaceuticals' shares. Their predictions range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' share price to reach $25.00 in the next twelve months. View Analyst Ratings for Aquinox Pharmaceuticals.

What are Wall Street analysts saying about Aquinox Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aquinox Pharmaceuticals stock:

  • 1. Needham & Company LLC analysts commented, "Aquinox reported 3Q17 financial results this week. Phase 3 LEADERSHIP 301 trial of rosiptor continues to enroll pts and company continues to guide for top-line results in 3Q18. We expect a positive outcome based on Phase 2 data and reiterate BUY." (11/9/2017)
  • 2. Cantor Fitzgerald analysts commented, "FDA advisory committee meeting could shed light on FDA views of IC/BPS. On December 7, the FDA will hold an advisory panel (details here) to discuss appropriate patient selection criteria and clinical trial design features, including acceptable endpoints, for demonstrating clinical benefit for drugs" to treat the condition. We believe the meeting could be important to raise awareness of the condition and establish expectations for how IC/BPS drugs should be developed." (11/9/2017)
  • 3. According to Zacks Investment Research, "Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. " (10/10/2017)

Are investors shorting Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals saw a drop in short interest in the month of October. As of October 13th, there was short interest totalling 573,008 shares, a drop of 20.6% from the September 29th total of 721,680 shares. Based on an average trading volume of 49,508 shares, the days-to-cover ratio is currently 11.6 days. Approximately 2.5% of the shares of the stock are sold short.

Who are some of Aquinox Pharmaceuticals' key competitors?

Who are Aquinox Pharmaceuticals' key executives?

Aquinox Pharmaceuticals' management team includes the folowing people:

  • David J. Main, Co-Founder, President and Chief Executive Officer and Chairman of the Board (Age 50)
  • Kamran Alam, Chief Financial Officer, Vice President - Finance (Age 40)
  • Lloyd Mackenzie, Vice President - Technical Operations and Planning (Age 47)
  • David Chilton Mitchell, Vice President - Global Regulatory Affairs & Quality Assurance (Age 59)
  • Barbara Troupin M.D., Chief Medical Officer, Vice President - Clinical Development (Age 48)
  • Robert E. Pelzer, Lead Independent Director (Age 63)
  • Gary J. Bridger Ph.D., Director (Age 52)
  • Daniel J. Levitt M.D., Ph.D., Director (Age 68)
  • Richard S. Levy M.D., Director (Age 59)
  • Kelvin M. Neu M.D., Director (Age 42)

Who owns Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Alyeska Investment Group L.P. (1.20%), University of Notre Dame DU Lac (0.81%), Sphera Funds Management LTD. (0.32%), Citadel Advisors LLC (0.06%) and Investment Centers of America Inc. (0.05%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker and David Main. View Institutional Ownership Trends for Aquinox Pharmaceuticals.

Who bought Aquinox Pharmaceuticals stock? Who is buying Aquinox Pharmaceuticals stock?

Aquinox Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including University of Notre Dame DU Lac, Citadel Advisors LLC, Sphera Funds Management LTD., Investment Centers of America Inc. and Alyeska Investment Group L.P.. View Insider Buying and Selling for Aquinox Pharmaceuticals.

How do I buy Aquinox Pharmaceuticals stock?

Shares of Aquinox Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aquinox Pharmaceuticals' stock price today?

One share of Aquinox Pharmaceuticals stock can currently be purchased for approximately $10.56.

How big of a company is Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals has a market capitalization of $247.79 million. The company earns $-37,000,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Aquinox Pharmaceuticals employs 38 workers across the globe.

How can I contact Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals' mailing address is 887 Great Northern Way Suite 450, VANCOUVER, BC V5T 4T5, Canada. The company can be reached via phone at +1-604-6299223 or via email at [email protected]


MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  95 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Aquinox Pharmaceuticals (NASDAQ:AQXP)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $25.00 (136.74% upside)

Consensus Price Target History for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Price Target History for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Analysts' Ratings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017Canaccord GenuityReiterated RatingBuy$22.00N/AView Rating Details
11/9/2017Needham & Company LLCReiterated RatingBuy$25.00N/AView Rating Details
11/9/2017Cantor FitzgeraldReiterated RatingBuy$28.00N/AView Rating Details
11/11/2016Leerink SwannReiterated RatingBuy$24.00N/AView Rating Details
8/5/2016Jefferies Group LLCBoost Price TargetHold$7.00 -> $9.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Earnings by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Earnings History by Quarter for Aquinox Pharmaceuticals (NASDAQ AQXP)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/20176/30/2017($0.59)($0.59)ViewListenView Earnings Details
5/9/20173/31/2017($0.51)($0.36)ViewN/AView Earnings Details
3/9/201712/31/2016($0.51)($0.48)ViewListenView Earnings Details
11/9/2016Q316($0.58)($0.46)ViewN/AView Earnings Details
8/4/2016Q2($0.41)($0.63)ViewN/AView Earnings Details
5/10/2016Q1($0.35)($0.39)ViewN/AView Earnings Details
11/10/2015Q315($0.45)($0.43)ViewN/AView Earnings Details
8/6/2015Q215($0.56)($0.44)ViewN/AView Earnings Details
5/12/2015Q115($0.83)($0.60)ViewN/AView Earnings Details
4/15/2015($0.57)($0.78)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.76)($0.78)ViewN/AView Earnings Details
11/4/2014Q3 2014($0.29)($0.59)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.27)($0.51)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)
2017 EPS Consensus Estimate: ($2.43)
2018 EPS Consensus Estimate: ($2.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.57)($0.57)($0.57)
Q2 20171($0.59)($0.59)($0.59)
Q3 20171($0.62)($0.62)($0.62)
Q4 20171($0.65)($0.65)($0.65)
Q1 20181($0.68)($0.68)($0.68)
Q2 20181($0.71)($0.71)($0.71)
Q3 20181($0.59)($0.59)($0.59)
Q4 20181($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Aquinox Pharmaceuticals (NASDAQ AQXP)

Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 95.51%
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Institutional Ownership by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ AQXP)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/5/2017David MainInsiderSell15,625$13.26$207,187.50View SEC Filing  
1/9/2017Bros. Advisors Lp BakerMajor ShareholderBuy398,062$17.18$6,838,705.16View SEC Filing  
9/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy2,783,605$12.25$34,099,161.25View SEC Filing  
3/16/2016Bros. Advisors Lp BakerMajor ShareholderBuy471,667$7.99$3,768,619.33View SEC Filing  
3/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy109,912$7.98$877,097.76View SEC Filing  
1/26/2016Bros. Advisors Lp BakerMajor ShareholderBuy140,786$10.80$1,520,488.80View SEC Filing  
1/20/2016Bros. Advisors Lp BakerMajor ShareholderBuy112,034$9.48$1,062,082.32View SEC Filing  
1/19/2016Bros. Advisors Lp BakerMajor ShareholderBuy78,045$9.11$710,989.95View SEC Filing  
1/15/2016Bros. Advisors Lp BakerMajor ShareholderBuy202,623$8.28$1,677,718.44View SEC Filing  
9/10/2015Bros. Advisors Lp BakerMajor ShareholderBuy2,480,032$15.50$38,440,496.00View SEC Filing  
8/24/2015David Chilton MitchellVPBuy3,575$17.81$63,670.75View SEC Filing  
8/12/2015Kamran AlamCFOSell29,079$18.67$542,904.93View SEC Filing  
8/12/2015Lloyd MackenzieVPSell35,887$18.67$670,010.29View SEC Filing  
12/17/2014& Johnson JohnsonMajor ShareholderSell8,100$7.62$61,722.00View SEC Filing  
12/12/2014& Johnson JohnsonMajor ShareholderSell5,000$7.51$37,550.00View SEC Filing  
12/10/2014& Johnson JohnsonMajor ShareholderSell8,300$7.72$64,076.00View SEC Filing  
12/9/2014& Johnson JohnsonMajor ShareholderSell5,000$7.73$38,650.00View SEC Filing  
12/8/2014& Johnson JohnsonMajor ShareholderSell2,000$7.69$15,380.00View SEC Filing  
12/5/2014& Johnson JohnsonMajor ShareholderSell15,900$7.76$123,384.00View SEC Filing  
12/1/2014& Johnson JohnsonMajor ShareholderSell1,200$7.54$9,048.00View SEC Filing  
11/26/2014& Johnson JohnsonMajor ShareholderSell2,000$7.75$15,500.00View SEC Filing  
11/24/2014& Johnson JohnsonMajor ShareholderSell9,500$8.14$77,330.00View SEC Filing  
3/12/2014Pfizer IncMajor ShareholderBuy272,727$11.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Aquinox Pharmaceuticals (NASDAQ AQXP)

Source:
DateHeadline
Aquinox Pharmaceuticals, Inc. (AQXP) Stock Rating Reaffirmed by Canaccord GenuityAquinox Pharmaceuticals, Inc. (AQXP) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - November 21 at 3:24 PM
FY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (AQXP) Lifted by Cantor FitzgeraldFY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (AQXP) Lifted by Cantor Fitzgerald
www.americanbankingnews.com - November 15 at 7:32 AM
Leerink Swann Weighs in on Aquinox Pharmaceuticals, Inc.s FY2017 Earnings (AQXP)Leerink Swann Weighs in on Aquinox Pharmaceuticals, Inc.'s FY2017 Earnings (AQXP)
www.americanbankingnews.com - November 13 at 3:58 AM
Aquinox Pharmaceuticals, Inc. (AQXP) Forecasted to Post Q1 2018 Earnings of ($0.68) Per ShareAquinox Pharmaceuticals, Inc. (AQXP) Forecasted to Post Q1 2018 Earnings of ($0.68) Per Share
www.americanbankingnews.com - November 10 at 10:56 AM
Aquinox Pharmaceuticals (AQXP) Buy Rating Reiterated at Needham & Company LLCAquinox Pharmaceuticals' (AQXP) Buy Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - November 9 at 3:42 PM
Aquinox Pharmaceuticals, Inc. (AQXP) Receives Buy Rating from Cantor FitzgeraldAquinox Pharmaceuticals, Inc. (AQXP) Receives Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - November 9 at 10:54 AM
Aquinox reports 3Q lossAquinox reports 3Q loss
finance.yahoo.com - November 8 at 6:10 PM
 Analysts Anticipate Aquinox Pharmaceuticals, Inc. (AQXP) Will Post Earnings of -$0.62 Per Share Analysts Anticipate Aquinox Pharmaceuticals, Inc. (AQXP) Will Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - November 7 at 5:30 AM
Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Recommendation of "Hold" from BrokeragesAquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 5 at 1:42 PM
Aquinox Pharmaceuticals, Inc. (AQXP) to Release Earnings on TuesdayAquinox Pharmaceuticals, Inc. (AQXP) to Release Earnings on Tuesday
www.americanbankingnews.com - October 31 at 7:44 AM
Aquinox Pharmaceuticals Inc (AQXP) Sees Significant Decrease in Short InterestAquinox Pharmaceuticals Inc (AQXP) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - October 29 at 1:50 AM
Oversold Conditions For Aquinox Pharmaceuticals (AQXP)Oversold Conditions For Aquinox Pharmaceuticals (AQXP)
www.thestreet.com - October 19 at 4:35 PM
Zacks: Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (AQXP) to Announce -$0.62 EPSZacks: Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (AQXP) to Announce -$0.62 EPS
www.americanbankingnews.com - October 18 at 2:24 PM
Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Recommendation of "Hold" from AnalystsAquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 11 at 4:42 PM
Aquinox Pharmaceuticals, Inc. (AQXP) Downgraded by Zacks Investment Research to "Sell"Aquinox Pharmaceuticals, Inc. (AQXP) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - October 10 at 5:46 PM
Innoviva (INVA) & Aquinox Pharmaceuticals (AQXP) Head-To-Head ReviewInnoviva (INVA) & Aquinox Pharmaceuticals (AQXP) Head-To-Head Review
www.americanbankingnews.com - October 10 at 2:16 PM
Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare ConferenceAquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 4:25 PM
Reviewing Aquinox Pharmaceuticals (AQXP) & Its PeersReviewing Aquinox Pharmaceuticals (AQXP) & Its Peers
www.americanbankingnews.com - September 18 at 4:28 AM
Aquinox Pharmaceuticals, Inc. (AQXP) Given Consensus Recommendation of "Hold" by AnalystsAquinox Pharmaceuticals, Inc. (AQXP) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 4:54 PM
Aquinox Pharmaceuticals: Buy, Sell Or Hold? - Seeking AlphaAquinox Pharmaceuticals: Buy, Sell Or Hold? - Seeking Alpha
seekingalpha.com - September 1 at 9:35 PM
Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome - GlobeNewswire (press release)Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome - GlobeNewswire (press release)
globenewswire.com - August 29 at 9:24 PM
Aquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain SyndromeAquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
www.streetinsider.com - August 29 at 2:07 AM
Collegium Pharmaceutical (COLL) and Aquinox Pharmaceuticals (AQXP) Head-To-Head ComparisonCollegium Pharmaceutical (COLL) and Aquinox Pharmaceuticals (AQXP) Head-To-Head Comparison
www.americanbankingnews.com - August 29 at 12:22 AM
Aquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder ... - StreetInsider.comAquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder ... - StreetInsider.com
www.streetinsider.com - August 28 at 9:07 PM
Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain SyndromeAquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
feeds.benzinga.com - August 28 at 9:46 AM
Aquinox Pharmaceuticals, Inc. (AQXP) Expected to Post Earnings of -$0.62 Per ShareAquinox Pharmaceuticals, Inc. (AQXP) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - August 23 at 12:20 PM
Aquinox Pharmaceuticals, Inc. (AQXP) Given Average Rating of "Buy" by AnalystsAquinox Pharmaceuticals, Inc. (AQXP) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 22 at 4:36 PM
Dr. Reddys Laboratories (RDY) versus Aquinox Pharmaceuticals (AQXP) Head-To-Head ContrastDr. Reddy's Laboratories (RDY) versus Aquinox Pharmaceuticals (AQXP) Head-To-Head Contrast
www.americanbankingnews.com - August 22 at 4:16 PM
Analyzing the Financial Health of Biotech Companies - PR Newswire (press release)Analyzing the Financial Health of Biotech Companies - PR Newswire (press release)
www.prnewswire.com - August 17 at 10:27 PM
FY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Increased by AnalystFY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Increased by Analyst
www.americanbankingnews.com - August 10 at 1:50 PM
Aquinox Pharmaceuticals (AQXP) CEO David Main on Q2 2017 Results - Earnings Call Transcript - Seeking AlphaAquinox Pharmaceuticals' (AQXP) CEO David Main on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 3:52 PM
Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results - GlobeNewswire (press release)Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 3:52 PM
Investor Network: Aquinox Pharmaceuticals, Inc. to Host Earnings CallInvestor Network: Aquinox Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 8 at 3:52 PM
Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial ResultsAquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 3:51 PM
Aquinox reports 2Q lossAquinox reports 2Q loss
finance.yahoo.com - August 8 at 3:51 PM
Aquinox Pharmaceuticals, Inc. (AQXP) Issues  Earnings ResultsAquinox Pharmaceuticals, Inc. (AQXP) Issues Earnings Results
www.americanbankingnews.com - August 8 at 2:24 PM
Aquinox to Present at Canaccord Genuity 37th Annual Growth ConferenceAquinox to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 2 at 4:50 PM
Aquinox to Present at Canaccord Genuity 37th Annual Growth ConferenceAquinox to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 2 at 4:50 PM
Aquinox Pharmaceuticals to Announce Second Quarter 2017 Financial ResultsAquinox Pharmaceuticals to Announce Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 4:59 PM
Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Rating of "Hold" from AnalystsAquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 4:39 PM
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) to Release Earnings on WednesdayAquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) to Release Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:20 AM
Analyzing Aquinox Pharmaceuticals (AQXP) and Teligent (TLGT)Analyzing Aquinox Pharmaceuticals (AQXP) and Teligent (TLGT)
www.americanbankingnews.com - July 19 at 8:51 AM
 Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Will Post Earnings of -$0.59 Per Share Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - July 13 at 10:20 PM
Corium International (CORI) Catches Eye: Stock Jumps 11.9%Corium International (CORI) Catches Eye: Stock Jumps 11.9%
finance.yahoo.com - July 8 at 6:21 AM
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Given Average Rating of "Buy" by BrokeragesAquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 4:58 PM
BRIEF-Aquinox Pharmaceuticals Qtrly loss per share $0.36BRIEF-Aquinox Pharmaceuticals Qtrly loss per share $0.36
www.reuters.com - May 11 at 3:59 PM
Aquinox Pharma (AQXP) Names Kelvin Neu and Richard Levy to Board of DirectorsAquinox Pharma (AQXP) Names Kelvin Neu and Richard Levy to Board of Directors
www.streetinsider.com - March 28 at 10:31 AM
AQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements andAQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
biz.yahoo.com - March 28 at 10:31 AM
Aquinox Pharmaceuticals (AQXP) Presents At Oppenheimer 27th Annual Healthcare Conference - SlideshowAquinox Pharmaceuticals (AQXP) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 22 at 9:08 PM
AQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal OfficersAQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 16 at 5:06 PM

Social Media

Financials

Chart

Aquinox Pharmaceuticals (NASDAQ AQXP) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.